The medical insurance price of lorlatinib in 2024 revealed

Lorlatinib (Lorlatinib), this third-generation ALKtyrosine kinase inhibitor (TKI) carefully developed by Pfizer, is being used in ALK with its excellent efficacy. span>ALKpositive or ROS1positive advanced non-small cell lung cancer (NSCLC) plays a pivotal role in the treatment. Not only can it effectively overcome multiple drug-resistant mutations in the ALK gene, it has also shown extraordinary strength in the treatment of central nervous system metastasis.

So,What is the price of lorlatinib in 2024 under the medical insurance policy?

Domestic price and medical insurance overview: In China, lorlatinib has long been on the market and has been fortunately included in the national medical insurance directory. This policy adjustment has undoubtedly brought good news to many patients, significantly reducing the originally high cost of treatment. However, even so, patients still have to bear a monthly cost of about 10,000 to 20,000 yuan, and the specific amount needs to be determined based on local reimbursement ratios and hospital policies. Therefore, it is recommended that patients consult their local hospital or medical insurance agency before purchasing to obtain the most accurate price information.

International market price comparison: Looking internationally, the price of lorlatinib shows different trends due to regional differences. For example, in Turkey, the price of the original drug is relatively affordable, about more than 7,000 yuan; in Hong Kong, China, the price has climbed to about 30,000 yuan, which is undoubtedly a large expense for patients.

In addition, there are also generic versions of drugs from Laos and Bangladesh on the market, which provide patients with more choices at low prices (ranging from about one thousand yuan to several thousand yuan per month). However, patients must exercise caution when choosing generic drugs and ensure that they are purchased from formal channels to ensure the quality and efficacy of the drugs.

With its potent anti-cancer ability and good tolerability, lorlatinib has become an indispensable treatment option for ALKpositiveNSCLC patients. However, the high cost of treatment is still a problem faced by many patients. Therefore, it is recommended that patients make the wisest choice based on their own financial situation, combined with local medical insurance policies and hospital quotations. At the same time, patients who are considering using generic drugs need to be extra cautious to ensure the formality of the source of the drugs to protect their own health.

xa0

Reference materials

1.Pfizer official website:https://www.pfizer.com

2.National Health Insurance Administration of China:http://www.nhsa.gov.cn